Related Experiment Videos
Cefpodoxime proxetil vs. penicillin V in pediatric streptococcal pharyngitis/tonsillitis
A S Dajani1, S L Kessler, R Mendelson
1Department of Pediatrics, Wayne State University School of Medicine, Detroit, MI.
Insights
Cefpodoxime proxetil effectively treats pediatric Group A streptococcal pharyngitis, showing higher S. pyogenes eradication rates than penicillin V. Both antibiotics were well-tolerated, offering alternatives for strep throat treatment.
Area of Science:
- Pediatric infectious diseases
- Antimicrobial therapy
- Pharmacology
Background:
- Group A streptococcal (Group A Strep) pharyngitis and tonsillitis are common pediatric infections.
- Penicillin V has been the standard treatment, but concerns about resistance and adherence exist.
- Evaluating alternative antibiotics like cefpodoxime proxetil is crucial for effective management.
Purpose of the Study:
- To compare the safety and efficacy of cefpodoxime proxetil versus penicillin V for treating pediatric Group A Strep pharyngitis.
- To assess clinical outcomes and microbiologic eradication rates of S. pyogenes.
Main Methods:
- Multicenter, randomized, parallel-group, observer-blinded trial involving pediatric patients.
- Cefpodoxime proxetil (5 mg/kg BID for 10 days) compared with penicillin V (13.4 mg/kg TID for 10 days).
- Safety and efficacy evaluated through clinical assessments and microbiologic cultures at multiple time points.
Main Results:
- Both cefpodoxime proxetil and penicillin V were well-tolerated, with mild gastrointestinal complaints reported.
- Comparable clinical cure rates were observed: 83.8% for cefpodoxime proxetil and 77.5% for penicillin V.
- Significantly higher eradication of S. pyogenes was achieved with cefpodoxime proxetil (93.1%) compared to penicillin V (81.2%) (P < 0.01).
Conclusions:
- Cefpodoxime proxetil is a safe and effective alternative for treating pediatric Group A streptococcal pharyngitis and tonsillitis.
- Cefpodoxime proxetil demonstrated superior microbiologic eradication of S. pyogenes compared to penicillin V.
- The findings support cefpodoxime proxetil as a viable treatment option, potentially improving therapeutic outcomes.
Abstract:
This multicenter, randomized, parallel treatment, observer-blinded study was designed to evaluate the safety and efficacy of cefpodoxime proxetil (5 mg/kg twice daily for 10 days) compared with penicillin V (13.4 mg/kg three times daily for 10 days) for treatment of Group A streptococcal pharyngitis and tonsillitis in pediatric patients. Clinical and microbiologic results were evaluated before therapy, during therapy (Study Days 3 to 5), at the end of therapy (Study Days 14 to 18) and at long term follow-up (Study Days 30 to 32). Both drugs were well-tolerated in 578 patients evaluable for safety. Mild gastrointestinal complaints were noted in 6.7% of 386 cefpodoxime-treated patients and in 5.2% of 192 penicillin-treated patients. In 413 patients evaluable for efficacy, both treatment regimens resulted in comparably favorable clinical outcome; cure rates were 83.8% for 275 cefpodoxime-treated patients and 77.5% for 138 penicillin-treated patients. However, eradication of S. pyogenes at end of therapy was significantly higher with cefpodoxime (93.1%) than with penicillin (81.2%) (P < 0.01). Cefpodoxime proxetil provides an effective alternative to penicillin V for the treatment of streptococcal pharyngitis and tonsillitis.